Stealth Bio Shares Trading Higher On Pre-Clinical Presentation Of Neuromuscular Disease Candidate
Stealth BioTherapeutics (NASDAQ: MITO) presented Pre-Clinical clinical results of SBT-272 for patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at the Keystone Neurodegeneration Symposium in Keystone, held June 5-9, 2022.
